The FAB classification for acute myeloid leukaemia - is it outdated?

Netherlands Journal of Medicine

Volumn 49, Issue 3, 1996, Pages 126-131

  Segeren, Christine M ^a   Van 'T Veer, Mars B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukaemia; Cytogenetics; FAB classification; Immunophenotyping

Indexed keywords

CANCER CLASSIFICATION; CYTOGENETICS; HUMAN; MYELOID LEUKEMIA; REVIEW;

EID: 0030245637     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/0300-2977(96)00024-1     Document Type: Review

References (53)

1. [1] Bennett JM, Catovsky D, Daniel M-T, et al. Proposals for the classification of the acute leukaemias. Br J Haematol 1976;33:451-458.
2. [2] Bennett JM, Catovsky D, Daniel M-T, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985;103:620-625.
3. [3] Catovsky D, Matutes E, Buccheri V, et al. A classification of acute leukaemia for the 1990s. Ann Hematol 1991;62:16-21.
4. [4] Bennett JM, Catovsky D, Daniel M-T, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 1991;78:325-329.
5. [5] Bennett JM, Catovsky D, Daniel M-T, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Ann Intern Med 1985; 103:460-462.
6. [6] Knapp W, Dörken B, Rieber P, Schmidt RE, Stem H, von dem Borne AEG Kr. CD antigens 1989. Blood 1989;74:1448-1450.
7. [7] Bennett JM, Catovsky MT, et al. The French-American-British (FAB) Cooperative Group 1981. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol 1981;47:553-561.
8. [8] First MIC Cooperative Study Group. Morphologic, immunologic and cytogenetic (MIC) working classification of acute lymphoblastic leukaemias. Cancer Genet Cytogenet 1986;23:189-197.
9. [9] Hayhoe FGJ. Classification of acute leukaemias. Blood Rev 1988;2:186-193.
10. [10] Lai JL, Fenaux P, Zandecki M, Nelken B, Huart JJ, Deminatti M. Cytogenetic studies in 30 patients with Burkitt's lymphoma or L3 acute lymphoblastic leukaemia with special reference to additional chromosome abnormalities. Ann Genet 1989;32:26-31.
11. [11] Third International Workshop on Chromosomes in Leukemia. Chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia. Cancer Res 1983;43:868-873.
12. [12] Seeker-Walker LM. The prognostic implications of chromosomal findings in acute lymphoblastic leukemia. Cancer Genet Cytogenet 1984;11:233-241.
13. [13] Bennett JM, Catovsky D, Daniel M-T, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;189-199.
14. [14] Browman GP, Neame PB, Soamboonsrup P. The contribution of cytochemistry and immunophenotyping to the reproducibility of the FAB classification in acute leukemia. Blood 1986;68:900-905.
15. [15] Head DR, Savage RA, Cerezo L, et al. Reproducibility of the French-American-British classification of acute leukemia: The Southwest Oncology Group experience. Am J Hematol 1985;18:45-57.
16. [16] Drexler HG. Classification of acute myeloid leukemias. A comparison of FAB and immunophenotyping. Leukemia 1987;1:697-705.
17. [17] Whittacker JA, Withey J, Powell DEB, Parry TE, Khurshid M. Leukemia classification: a study of the accuracy of diagnosis in 456 patients. Br J Haematol 1979;41:177-184.
18. [18] Dick FF, Armitage JO, Burns CP. Diagnostic concurrence in the subclassification of adult acute leukemia using French-American-British criteria. Cancer 1982;49:916-920.
19. [19] Bain BJ. Leukemia diagnosis. A guide to the FAB classification. London: Wolfe Publishing, 1993.
20. [20] Linch DC, Allen C, Beverly PCL, Bynoe AG, Scott CS, Hogg N. Monoclonal antibodies differentiating between monocytic and myelomonocytic variants of AML. Blood 1983;63:566-573.
21. [21] San Miguel JF, Gonzalez M, Canizo MC, Anta JP, Zola H, Lopez Borrasca A. Surface marker analysis in acute myeloid leukaemia and correlation with the FAB classification. Br J Haematol 1986;64:547-560.
22. [22] Erber WN, Asbahr H, Rule SA, Scott CS. Unique immunophenotype of acute promyelocytic leukemia as defined by CD9 and CD68 antibodies. Br J Haematol 1994;88:101-104.
23. [23] Larson RA, Kondo K, Vardiman JW. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984;76:827-841.
24. [24] Segeren CM, de Jong-Gerrits GCMM, van 't Veer MB. AML-M0: clinical entity or waste basket for immature blastic leukaemias? A description of 14 patients. Ann Haematol 1995;70:297-300.
25. [25] Lee EJ, Pollak A, Leavitt RD, Testa JR, Schiffer CA. Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. Blood 1987;70:1400-1406.
26. [26] Venditti A, Del Poeta G, Stasi R, et al. Minimally differentiated acute myeloid leukaemia (AML-M0): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases. Br J Haematol 1994;88:784-793.
27. [27] Sempere A, Jarque L, Guinot M, et al. Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases. Leukemia Lymphoma 1993;12:103-108.
28. [28] Cuneo A, Ferrant A, Michaux JL, et al. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia:correlation with clinicobiologic findings. Blood 1995;85:3688-3694.
29. [29] Fourth International Workshop on Chromosomes in Leukemia, 1982. Overview of association between chromosomal pattern and cell morphology, age, sex and race. Cancer Genet Cytogenet 1984;11:265-283.
30. [30] Grignani F, Fagiolo M, Alcalay M. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994;83:10-25.
31. [31] Larson RA, Williams SF, Le Beau MM, et al. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favourable prognosis. Blood 1986;68:1242-1249.
32. [32] Walker H, Smith FJ, Betts DR. Cytogenetics in acute myeloid leukaemia. Blood Rev 1994;8:30-36.
33. [33] Third MIC Cooperative Study Group. Recommendations for a morphologic, immunologic and cytogenetic (MIC) working classification of primary and therapy-related myelodysplastic disorders. Cancer Genet Cytogenet 1988;32:1-10.
34. [34] Yunis JJ, Lobell M, Arnesen MA, et al. Refined chromosomal study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myeloid leukemia. Br J Haematol 1988;68:189-194.
35. [35] Campara D, Hansen-Hagge TE, Matutes E, et al. Phenotypic, genotypic, cytochemical and ultrastructural characterization of acute undifferentiated leukemia. Leukemia 1990;4:620-624.
36. [36] LeMaistre A, Childs A, Hirsh-Ginsberg C, et al. Heterogeneity in acute undifferentiated leukemia. Hematol Pathol 1988;2:79-89.
37. [37] Matutes E, Catovsky D. The value of scoring systems for the diagnosis of biphenotypic leukemia and mature B-cell disorders. Leukemia Lymphoma 1994;13:11-14.
38. [38] European Group for the Immunological Characterization of Leukemias (EGIL): Bene MC, Castoldi G, Knapp W et al. Proposals for the immunological classification of acute leukemias. Leukemia 1995;9:1783-1786.
39. [39] Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR. Prognostic impact of cytogenetic abnormalities in patients with the de novo acute nonlymphocytic leukemia. Blood 1989;73:263-270.
40. [40] Tucker J, Dorey E, Gregory WY. Immunophenotype of blast cells in acute myeloid leukemia may be useful predictor for outcome. Hematol Oncol 1990;8:47-58.
41. [41] Campos L, Guyotat D, Archimbaud E. Surface marker expression in adult acute myeloid leukaemia: correlation with initial characteristics, morphology and response to therapy. Br J Haematol 1989;72:161-166.
42. [42] Del Poeta G, Stasi R, Venditti A, et al. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 1994;8:388-394.
43. [43] Lo Coco F, De Rossi G, Pasqualetti D. CD7 positive acute myeloid leukemia: a subtype associated with cell immaturity. Br J Haematol 1989;73:480-485.
44. [44] Second MIC Cooperative Study Group. Morphologic, immunologic and cytogenetic (MIC) working classification of the acute myeloid leukemias. Br J Haematol 1988;68:487-494.
45. [45] Gray JW, Kuo WL, Liang J, et al. Analytical approaches to detection and characterization of disease-linked chromosome aberrations. Bone Marrow Transplant 1990;6:14-19.
46. [46] Nylund SJ, Ruutu T, Saarinen U, Larramendy ML, Knuutila S. Detection of minimal residual disease using fluorescence DNA in situ hybridization:a follow-up in leukemic and lymphoma patients. Leukemia 1994;8:587-596.
47. [47] Anastasi J, Vardiman JW, Rudinsky R, et al. Direct correlation of cytogenetic findings with cell morphology using in situ hybridization and analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acute lymphoblastic leukemia. Blood 1991;77:2456-2462.
48. [48] Weber-Mathiesen K, Winkemann M, Muller-Hemerlink A, Schlegelberger B, Grote W. Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a correlation to characterization of tumor cells. J Histochem Cytochem 1992;40:171-175.
49. [49] Lo Coco F, Diverio D, Pandolfi PP, et al. Molecular evaluation of residual disease as predictor of relapse in acute promyelocytic leukaemia. Lancet 1992;340:1437-1438.
50. [50] Miller Jr WH, Kakizuka A, Frankel SR, et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor a clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992;89:2694-2698.
51. [51] Nisson PE, Watkins PC, Sacchi N. Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene as chromosome 8 in t(8;21) leukemic cells. Cancer Genet Cytogenet 1992;63:81-88.
52. [52] Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlympho-blastic leukemia cells at diagnosis. Blood 1992;79:473-476.
53. [53] Zöchbauer S, Gsur A, Brunner R, Kyrle PA, Lechner K, Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994;8:974-977.